As part of its strategy and expansion plans, Macro was converted in 2010 to a limited liability company to provide a more structured corporate governance framework for the growing operations of the company. In the same year, the company established its first production facility in an industrial area in Badr City, shifting to in-house production of 25 products.
To maintain the quality standards, every plant has well-defined procedures and systems in place in compliance with the requirements of the Current Good Manufacturing Practices (cGMP), WHO, PIC’s and EU GMP in order to ensure that our operating procedures meet the very exacting standards of regulators like the US FDA, EMA, HC, WHO and TGA among others.
Each site has well-trained personnel for quality control along with a regulatory affairs department ensuring strict adherence to quality systems and procedures. The teams are guided by a Corporate Quality Unit (CQU) that ensures that the latest updates in GMP are being translated into guidelines, standard operating procedures (SOPs) and protocols.
The teams ensure that these guidelines are implemented to deliver quality products time after time. In addition, the manufacturing plants are audited by an autonomous Corporate Compliance Department with a view to ensuring compliance and conformance.
Our unwavering commitment to quality goes beyond ourselves. We insist that our business partners comply with national and international regulatory and business standards which are aligned with those of our own.
Our own quality standards are constantly benchmarked against global best practices. This means that these are constantly upgraded to keep pace with the evolving dynamics of the global environment.
We remain committed to the highest levels of quality and will ensure that all our facilities, offices and legal entities continue to meet the exemplary standards that are expected of a global pharmaceutical company.